31.2% of Non-Hispanic Black women aged 20 to 64 have anemia. Among Non-Hispanic White women in the same age group, that number is 7.8%. That four-fold gap is not a rounding error or a quirk of small samples. It is one of the starkest racial disparities in a common, treatable condition that rarely makes headlines.

Anemia, defined here as hemoglobin below 12 g/dL for women, is not exotic. It causes fatigue, cognitive fog, reduced work capacity, and complications in pregnancy. It is also, in many cases, correctable. The question the data raises is why so many women are carrying it undetected.

A Four-Fold Gap That Dwarfs Every Other Comparison

The racial disparity in anemia prevalence among women is not a gradient. It is a cliff.

Non-Hispanic Black women at 31.2% sit in a category of their own. Non-Hispanic Asian and Mexican American women both come in near 19%, more than double the White women's rate but still 12 percentage points below Black women. For context, the highest anemia prevalence among any male group in the data is 9.8%, among Other Hispanic men. Non-Hispanic Black women's rate is more than three times that figure.

The gender gap within race is equally striking. Non-Hispanic Black men have an anemia prevalence of 7.4%. Black women's rate of 31.2% is more than four times higher. That divergence points toward causes specific to women's physiology, including menstruation and reproductive health, but the scale of the disparity suggests something beyond biology alone is at work.

Income Doubles the Risk, But Doesn't Explain the Whole Story

Women living below the poverty line have an anemia prevalence of 19.1%, compared to 9.4% among women in the middle-high income group (income-to-poverty ratio above 3.5). That's roughly a doubling of risk across the income spectrum, and the average hemoglobin tracks with it: 12.96 g/dL at the bottom versus 13.29 g/dL at the top.

Nearly 1 in 5 women below the poverty line are anemic. That is a clinically actionable number. These are women who are more likely to be uninsured or underinsured, less likely to receive routine blood work, and more likely to attribute fatigue to stress or overwork rather than a measurable deficiency.

Income explains part of the racial disparity, but not all of it. Non-Hispanic White women, even those in lower income brackets, do not approach the 31.2% prevalence seen among Black women overall. The income gradient and the racial gap are overlapping but distinct phenomena.

More Than Half of Anemic Young Women Don't Fit the Iron-Deficiency Profile

Here is where the data gets complicated for clinicians. Among anemic women aged 20 to 49, 47.6% have low mean corpuscular volume (MCV below 80 fL), the classic marker of iron-deficiency anemia. That's the type most people picture when they think of anemia in young women: low iron, fix the diet, take a supplement.

But 52.4% of anemic women in this age group have normal MCV, meaning normocytic anemia. Their red blood cells are normal-sized. Iron deficiency is not the primary driver. Normocytic anemia is associated with chronic disease, inflammation, kidney disease, and other systemic conditions that don't respond to iron supplementation.

That majority subgroup is the harder clinical problem. A woman who goes to her doctor tired, gets a hemoglobin check, and is told to eat more spinach may be getting the wrong answer entirely. If the underlying driver is chronic inflammation or an undiagnosed condition, the treatment path is completely different and considerably more complex.

The implication is that anemia screening, where it happens at all, may be systematically misclassifying the majority of cases in reproductive-age women. Given that 31.2% of Non-Hispanic Black women in this age range are anemic, and that more than half of anemic young women have a non-iron-deficiency pattern, the gap between what's being detected and what's being correctly treated may be wider than anyone has measured.